A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture

NCT05352516 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

514

Enrollment

INDUSTRY

Sponsor class

Conditions

Postmenopausal

Interventions

BIOLOGICAL: HLX14
BIOLOGICAL: Prolia®

Sponsor

Shanghai Henlius Biotech